181 related articles for article (PubMed ID: 30443181)
1. Inhibition of AKT suppresses the initiation and progression of
Baek HJ; Kim SE; Kim JK; Shin DH; Kim TH; Kim KG; Deng CX; Kim SS
Int J Biol Sci; 2018; 14(13):1769-1781. PubMed ID: 30443181
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Estrogen Signaling Reduces the Incidence of
Baek HJ; Kim SE; Choi EK; Kim JK; Shin DH; Park EJ; Kim TH; Kim JY; Kim KG; Deng CX; Kim SS
Int J Biol Sci; 2018; 14(12):1755-1768. PubMed ID: 30416390
[TBL] [Abstract][Full Text] [Related]
3. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Wang C; Bai F; Zhang LH; Scott A; Li E; Pei XH
Breast Cancer Res; 2018 Jul; 20(1):74. PubMed ID: 29996906
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Akt/mTOR pathway in Brca1-deficient cancers.
Xiang T; Jia Y; Sherris D; Li S; Wang H; Lu D; Yang Q
Oncogene; 2011 May; 30(21):2443-50. PubMed ID: 21242970
[TBL] [Abstract][Full Text] [Related]
5. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
6. Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer.
Yeo SK; Paul R; Haas M; Wang C; Guan JL
Autophagy; 2018; 14(7):1214-1225. PubMed ID: 29938573
[TBL] [Abstract][Full Text] [Related]
7. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
[TBL] [Abstract][Full Text] [Related]
9. p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.
Scott A; Bai F; Chan HL; Liu S; Ma J; Slingerland JM; Robbins DJ; Capobianco AJ; Pei XH
Oncotarget; 2016 Dec; 7(51):84496-84507. PubMed ID: 27811360
[TBL] [Abstract][Full Text] [Related]
10. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
Weaver Z; Montagna C; Xu X; Howard T; Gadina M; Brodie SG; Deng CX; Ried T
Oncogene; 2002 Aug; 21(33):5097-107. PubMed ID: 12140760
[TBL] [Abstract][Full Text] [Related]
11. BRCA1-IRIS overexpression promotes formation of aggressive breast cancers.
Shimizu Y; Luk H; Horio D; Miron P; Griswold M; Iglehart D; Hernandez B; Killeen J; ElShamy WM
PLoS One; 2012; 7(4):e34102. PubMed ID: 22511931
[TBL] [Abstract][Full Text] [Related]
12. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
13. Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing.
Sun H; Zeng J; Miao Z; Lei KC; Huang C; Hu L; Su SM; Chan UI; Miao K; Zhang X; Zhang A; Guo S; Chen S; Meng Y; Deng M; Hao W; Lei H; Lin Y; Yang Z; Tang D; Wong KH; Zhang XD; Xu X; Deng CX
Theranostics; 2021; 11(20):9967-9987. PubMed ID: 34815798
[No Abstract] [Full Text] [Related]
14. Negative Regulation of AKT Activation by BRCA1.
Xiang T; Ohashi A; Huang Y; Pandita TK; Ludwig T; Powell SN; Yang Q
Cancer Res; 2008 Dec; 68(24):10040-4. PubMed ID: 19074868
[TBL] [Abstract][Full Text] [Related]
15. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer.
Zhang L; Zhou Q; Qiu Q; Hou L; Wu M; Li J; Li X; Lu B; Cheng X; Liu P; Lu W; Lu Y
Mol Cancer; 2019 Oct; 18(1):144. PubMed ID: 31623606
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
Bai F; Chan HL; Scott A; Smith MD; Fan C; Herschkowitz JI; Perou CM; Livingstone AS; Robbins DJ; Capobianco AJ; Pei XH
Cancer Res; 2014 Nov; 74(21):6161-72. PubMed ID: 25239453
[TBL] [Abstract][Full Text] [Related]
17. Cholesteryl Ester Promotes Mammary Tumor Growth in MMTV-PyMT Mice and Activates Akt-mTOR Pathway in Tumor Cells.
Wei L; Lu X; Weng S; Zhu S; Chen Y
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34201030
[TBL] [Abstract][Full Text] [Related]
18. Progesterone receptor A stability is mediated by glycogen synthase kinase-3β in the Brca1-deficient mammary gland.
Wang S; Li Y; Hsu PH; Lee SY; Kim Y; Lee EYP
J Biol Chem; 2013 Sep; 288(36):26265-26274. PubMed ID: 23880761
[TBL] [Abstract][Full Text] [Related]
19. PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.
Bai F; Liu S; Liu X; Hollern DP; Scott A; Wang C; Zhang L; Fan C; Fu L; Perou CM; Zhu WG; Pei XH
Breast Cancer Res; 2021 Jan; 23(1):10. PubMed ID: 33478572
[TBL] [Abstract][Full Text] [Related]
20. Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.
Warmoes M; Jaspers JE; Pham TV; Piersma SR; Oudgenoeg G; Massink MP; Waisfisz Q; Rottenberg S; Boven E; Jonkers J; Jimenez CR
Mol Cell Proteomics; 2012 Jul; 11(7):M111.013334. PubMed ID: 22366898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
